Increased Plasma Levels of Adenylate Cyclase 8 and cAMP Are Associated with Obesity and Type 2 Diabetes: Results from a Cross-Sectional Study.
Samy M Abdel-HalimAshraf Al MadhounRasheeba NizamMotasem MelhemPreethi CherianIrina Al-KhairiDania HaddadMohamed Abu-FarhaJehad AbubakerMilad S BitarFahd Al-MullaPublished in: Biology (2020)
Adenylate cyclases (ADCYs) catalyze the conversion of ATP to cAMP, an important co-factor in energy homeostasis. Giving ADCYs role in obesity, diabetes and inflammation, we questioned whether calcium-stimulated ADCY isoforms may be variably detectable in human plasma. We report the results of a cross-sectional study assessing circulating levels of functional ADCY1, -3 and -8 in patients with T2D vs. non-diabetic (ND) controls in association with obesity. ADCY1 levels exhibited no significant change between ND and T2D groups. ADCY3 levels were lower in obese individuals, albeit not statistically significantly. In contrast, ADCY8 plasma levels were significantly higher in obese and T2D patients compared to controls (p = 0.001) and patients with T2D only (p = 0.039). ADCY8 levels correlated positively with body mass index and Hb1Ac levels. Parallel to the increased ADCY8 levels, significantly higher cAMP levels were observed in patients with T2D compared with ND controls, and further elevated in obese individuals, irrespective of T2D status. Additionally, cAMP levels positively correlated with fasting plasma glucose levels. In conclusion, the current cross-sectional study demonstrated elevated levels of circulating plasma ADCY8 and cAMP in obesity and T2D.
Keyphrases
- type diabetes
- metabolic syndrome
- weight loss
- insulin resistance
- adipose tissue
- chronic kidney disease
- magnetic resonance imaging
- end stage renal disease
- cardiovascular disease
- body mass index
- computed tomography
- newly diagnosed
- physical activity
- binding protein
- skeletal muscle
- protein kinase
- ejection fraction
- prognostic factors